ReviewThe Psychiatric clinics of North America2007
Psychiatric issues in multiple sclerosis.
Review in The Psychiatric clinics of North America, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 163 citations in OpenAlex.
- Mindfulness based interventions in multiple sclerosis--a systematic review.BMC neurology · 2014Pooled it
- Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.Journal of neurology · 2016Trial
- Psychosis in multiple sclerosis-a narrative review of an underestimated, but clinically significant problem.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Default modetwork connectivity and its clinical relevance for depression in multiple sclerosis: A scoping review.IBRO neuroscience reports · 2026Review
- Psychiatric comorbidities in multiple sclerosis patients and their relationship with clinical variables: A university hospital sample.Dusunen adam : Bakirkoy Ruh ve Sinir Hastaliklari Hastanesi yayin organi · 2026Article
- Multiple Sclerosis in the Emergency Department: A Retrospective Case-Control Study in a Large US Center.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Aerobic Exercise Training and Depressive Symptoms in People With Multiple Sclerosis: Brief Report on Default-Mode Network Resting-State Functional Connectivity.International journal of MS care · 2025Article
- Neuropsychiatric disorders among Ecuadorian patients with multiple sclerosis and neuromyelitis optica spectrum disorder.Frontiers in neurology · 2025Article
- Lifetime exposure to smoking and substance abuse may be associated with late-onset multiple sclerosis: a population-based case-control study.BMC neurology · 2024Article
- Assessing the Impact of the Mindfulness-Based Body Scan Technique on Sleep Quality in Multiple Sclerosis Using Objective and Subjective Assessment Tools: Single-Case Study.JMIR formative research · 2024Article
- Article
- Cognitive impairment in multiple sclerosis: "classic" knowledge and recent acquisitions.Arquivos de neuro-psiquiatria · 2023Article
- Neuroimmune, clinical and treatment challenges in multiple sclerosis-related psychoses.World journal of psychiatry · 2023Review
- Coping Strategies and Posttraumatic Growth Following Transient Ischemic Attack: A Qualitative Study.Journal of clinical medicine · 2023Article
- Interventions to Improve Quality of Life in Multiple Sclerosis: New Opportunities and Key Talking Points.Degenerative neurological and neuromuscular disease · 2023Review
- Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience.Journal of clinical psychology in medical settings · 2022Article
- The longitudinal relationship between fatigue, depression, anxiety, disability, and adherence with cognitive status in patients with early multiple sclerosis treated with interferon beta-1a.eNeurologicalSci · 2022Article
- Barriers to quality of life in patients with multiple sclerosis: a qualitative study.BMC neurology · 2022Article
- Physical and Mental Health Comorbidities Among Adults With Multiple Sclerosis.Mayo Clinic proceedings. Innovations, quality & outcomes · 2022Article
- Determining Prevalence of Depression and Covariates of Depression in a Cohort of Multiple Sclerosis Patients.Journal of central nervous system disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
MDD and anxiety disorders are highly prevalent among persons who have MS and have been associated with decreased adherence to MS treatment and poorer functional status and quality of life. Effective treatment is available for MDD, but this disorder continues to be underdetected and undertreated by MS providers. Treatment with pharmacotherapy is particularly challenging in this patient population, given the somatic symptom overlap between MS and depression and the increased burden of side effects. Larger randomized, controlled trials are needed to elucidate further the effectiveness of pharmacotherapy and to identify subgroups of patients who would benefit from this type of treatment for depression. There have been few rigorous studies of the prevalence and impact of anxiety disorders, substance use disorders, or serious mental illness such as bipolar disorder or schizophrenia, in MS samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.